

Phase 1 clinical development of PG-102, a next-generation GLP-1/GLP-2 dual agonist for treating obesity and diabetes



METABOLIC		Phase 1	
Product Type	Bispecific fusion protein		
Indication	Obesity, Type 2 Diabetes		
Target	GLP-1R and GLP-2R		
MOA(Mechanism of Action)	<p>Long-acting Fc</p> <p>A biased GLP-1R/GLP-2R dual agonist with extended PK properties</p> <ul style="list-style-type: none"> Relative potency of PG-102 against GLP-1 receptor and GLP-2 receptor is sophisticatedly optimized for simultaneously activation of both receptors. PG-102 also features NTIG®, a long-acting Fc platform technology, for a prolonged action 		
Competitiveness	Efficacy	• Superior quality of body weight loss compared to Tirzepatide Fat mass loss ↑ + lean mass loss ↓	Data 1
		• Breakthrough glycemic control compared to Semaglutide and Tirzepatide Glucose uptake ↑ + β-cell protection	Data 2
		• Comorbidity prevention in obesity/diabetes	Data 3
	Safety	• Improved safety & tolerability Gastrointestinal tract inflammation ↓	Data 3
Convenience	• Extended dosing interval allowing for at least biweekly to monthly administration		
Development Stage	Phase 1b		
Route of Administration	Subcutaneous injection		